Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer

Endocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)‐positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulard, Coralie, Ha Pham, Thuy, Drouet, Youenn, Jacquemetton, Julien, Surmielova, Ausra, Kassem, Loay, Mery, Benoite, Lasset, Christine, Reboulet, Jonathan, Treilleux, Isabelle, Marangoni, Elisabetta, Trédan, Olivier, Le Romancer, Muriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405064/
https://www.ncbi.nlm.nih.gov/pubmed/37458145
http://dx.doi.org/10.15252/emmm.202217248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405064/
https://www.ncbi.nlm.nih.gov/pubmed/37458145
http://dx.doi.org/10.15252/emmm.202217248

Ejemplares similares